(Q39181242)

English

Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma

scientific article published on 15 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma (English)

1 reference

Europe PubMed Central

9 September 2017

10

object named as

Michael P Manns

1 reference

Europe PubMed Central

9 September 2017

author name string

Martha M Kirstein

1

1 reference

Europe PubMed Central

9 September 2017

Aristeidis E Boukouris

2

1 reference

Europe PubMed Central

9 September 2017

Deepika Pothiraju

3

1 reference

Europe PubMed Central

9 September 2017

Laura E Buitrago-Molina

4

1 reference

Europe PubMed Central

9 September 2017

Silke Marhenke

5

1 reference

Europe PubMed Central

9 September 2017

Jutta Schütt

6

1 reference

Europe PubMed Central

9 September 2017

Johanna Orlik

7

1 reference

Europe PubMed Central

9 September 2017

Florian Kühnel

8

1 reference

Europe PubMed Central

9 September 2017

Jan Hegermann

9

1 reference

Europe PubMed Central

9 September 2017

Arndt Vogel

11

1 reference

Europe PubMed Central

9 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

15 March 2013

1 reference

Europe PubMed Central

9 September 2017

Liver International

1 reference

Europe PubMed Central

9 September 2017

33

1 reference

Europe PubMed Central

9 September 2017

780-793

1 reference

Europe PubMed Central

9 September 2017

5

1 reference

Europe PubMed Central

9 September 2017

Diagnosis and Treatment of Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Pivotal role of mTOR signaling in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

mTOR and P70 S6 kinase expression in primary liver neoplasms

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Pilot study: rapamycin in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

The use of lead citrate at high pH as an electron-opaque stain in electron microscopy

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Defining the role of mTOR in cancer

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

The role of TOR in autophagy regulation from yeast to plants and mammals

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Direct control of mitochondrial function by mTOR.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Rapamycin-sensitive induction of eukaryotic initiation factor 4F in regenerating mouse liver

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Control of autophagy by oncogenes and tumor suppressor genes

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

NVP-BEZ235 as a new therapeutic option for sarcomas.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12126

21 January 2018

Identifiers

10.1111/LIV.12126

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39181242&oldid=1811928223"